Drug spin-off trend gains traction with IPO by Hengrui offshoot
A company set up to develop Hengrui Pharma’s weight-loss drugs has made a strong debut on the U.S. equity market, building confidence in the “NewCo” business model Key Takeaways: Hengrui’s…
A healthy return: drug spin-off nets Keymed up to $320 million
The Chinese biotech set up a separate “NewCo” company for its autoimmune drug, beating the likely proceeds from a conventional out-licensing deal Key Takeaways: International drug rights were transferred to…
